Intest Res.
2023 Apr;21(2):273-273. 10.5217/ir.2021.00173.e.
Corrigendum: Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
- Affiliations
-
- 1Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- 2Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- 3Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- 4Digestive Diseases Research Center, University of Ulsan College of Medicine, Seoul, Korea
- 5Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
- 6Department of Internal Medicine, Seoul Paik Hospital, Inje University College of Medicine, Seoul, Korea
- 7Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea
- KMID: 2541901
- DOI: http://doi.org/10.5217/ir.2021.00173.e
Reference
-
1. Oh K, Hong HS, Ham NS, et al. Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study. Intest Res. 2023; 21:137–147.
Article
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
- The Phase 3 Trials of Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
- Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies
- Ustekinumab is effective in biological refractory Crohn's disease patients–regardless of approval study selection criteria
- Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study
